Edition:
United States

Rhythm Pharmaceuticals Inc (RYTM.OQ)

RYTM.OQ on NASDAQ Stock Exchange Global Market

27.13USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$27.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$33.80
52-wk Low
$21.38

Latest Key Developments (Source: Significant Developments)

Rhythm Pharmaceuticals reports Q3 loss of $1.78/shr
Tuesday, 14 Nov 2017 08:00am EST 

Nov 14 (Reuters) - Rhythm Pharmaceuticals Inc :Rhythm Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $1.78.Q3 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.Rhythm Pharmaceuticals Inc - ‍as of Sept 30, cash, cash equivalents, short-term investments were $30.4 million, as compared to $10.5 million as of Dec 31, 2016​.  Full Article

‍Orbimed Advisors reports 10.7 pct stake in Rhythm Pharmaceuticals ​
Friday, 20 Oct 2017 04:29pm EDT 

Oct 20 (Reuters) - Rhythm Pharmaceuticals Inc ::‍orbimed Advisors reports a 10.7 percent stake in Rhythm Pharmaceuticals Inc as of october 10 - sec filing​.  Full Article

Pfizer reports 5.4 pct passive stake in Rhythm Pharmaceuticals - ‍​SEC filing
Wednesday, 18 Oct 2017 03:45pm EDT 

Oct 18 (Reuters) - Pfizer Inc ::Pfizer Inc reports 5.4 percent passive stake in Rhythm Pharmaceuticals Inc as of October 10, 2017 - ‍​SEC filing.  Full Article

Rhythm Pharmaceuticals announces pricing of initial public offering
Wednesday, 4 Oct 2017 09:08pm EDT 

Oct 5 (Reuters) - Rhythm Pharmaceuticals Inc :Rhythm Pharmaceuticals Inc announces pricing of initial public offering.Says initial public offering of 7.05 million common shares priced at $17.00 per share.  Full Article

Rhythm Pharmaceuticals sees IPO of 6.7 mln shares priced between $14.00 and $16.00 per share‍​
Monday, 25 Sep 2017 06:49am EDT 

Sept 25 (Reuters) - Rhythm Pharmaceuticals Inc :sees IPO of 6.7 million shares of its common stock priced between $14.00 and $16.00 per share‍​ - SEC filing.  Full Article

BRIEF-Rhythm Pharmaceuticals reports Q3 loss of $1.78/shr

* Rhythm Pharmaceuticals reports third quarter 2017 financial results